Malignant pleural mesothelioma (MPM) is an uncommon, almost universally fatal, asbestos-induced malignancy. New and effective strategies for diagnosis, prognostication and treatment are urgently needed. Herein we review the advances in MPM achieved in 2017. While recent epidemiological data demonstrated that the incidence of MPM-related death continued to increase in United States between 2009 and 2015, new insight into the molecular pathogenesis and the immunological tumor microenvironment of MPM, for example, regarding the role of BRCA1 associated protein 1 (BAP1) and the expression programmed death receptor ligand 1 (PD-L1), are highlighting new potential therapeutic strategies. Furthermore, there continues to be an ever-expanding number of clinical studies investigating systemic therapies for MPM. These trials are primarily focused on immunotherapy using immune checkpoint inhibitors alone or in combination with other immuno-andnon-immuno therapies.
Lessons in Epidemiology and Occupational Medicine
Intra-individual biopersistence of asbestos fibers over time was analyzed in 12 longitudinally collected human lung tissue samples. The results suggested that the purportedly less carcinogenic chrysotile asbestos fibers also demonstrate a long biopersistance, and therefore likely account for a proportion of MPM cases 11 , confirming suggestions by pre-clinical studies 12 . A second large study provided insights into the dose-time-response relationship between occupational asbestos exposure and pleural mesothelioma, suggesting that initial high doses of asbestos, followed by low doses thereafter are associated with the highest risk 13 . Moreover, non-occupational asbestos exposure is an increasingly recognized risk factor for MPM. In this context a recent review and meta-analysis supported the critical need to evaluate MPM risk in communities with ambient asbestos or other carcinogenic fiber exposures 14 . Finally, in a large study across 230 countries over a 20 year period, the global burden of MPM deaths was extrapolated to about 38,400 per year, suggesting that it might be even higher than the most recently reported values 15 .
Developments in Diagnosis and Staging
Blood-based biomarkers serve several potential roles in MPM: diagnostic, prognostic, or predictive of response to specific therapies. The most studied blood-based biomarkers are mesothelin, osteopontin, fibulin-3 16 , and HMGB1 17 . In 2017, three meta-analyses respectively confirmed that pretreatment thrombocytosis 18 , elevated neutrophil-to-lymphocyte ratio 19 , and high serum levels of soluble mesothelin 20 are prognostic for poor survival. A recent study identified complement component 4d as a promising biomarker correlating with tumor volume, response to chemotherapy, and survival 21 . Other potentially useful blood based diagnostic markers for mesothelioma include midkine, calretinin and M A N U S C R I P T
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Mesothelioma 2017 miRNA 22, 23, 24, 25 . Deregulated miRNA levels of Let-7c-5p and miR-151a-5p in tissue may also be prognostic in MPM 26 . In addition, proteomic analysis of the secretome, including exosomes from MPM cells identified proteins that potentially enhance the growth and stress response, and inhibit adaptive immunity 27, 28 .
Clinical and pathological staging is important to determine disease prognosis and facilitate patient selection for multi-modality therapy. The IASLC Mesothelioma Staging Project for the 8 th edition of the AJCC/UICC staging manual updated TNM staging in MPM [29] [30] [31] . However the project database still overrepresented surgically treated patients and, despite recent advances in cross-sectional anatomic and functional imaging, and mediastinal lymph node sampling, clinical staging remains difficult. One challenge is the inability to distinguish tumor tissue from surrounding normal tissues for staging and follow-up using standard anatomic cross-sectional imaging. While the current version of the modified RECIST guidelines for MPM is more applicable to mesothelioma than RECIST 1.0 or 1.1, further researchbased optimization of response criteria for MPM is still required. Tumor volume is increasingly recognized as an anatomical, imaging-based prognostic factor, however valid and reliable measurement of this parameter across sites and software platforms is difficult 32 . Attempts to create an automated volumetric assessment of tumor volume for treatment response and prognostication have been difficult due to a lack of accuracy and reproducibility [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . The most promising results on the prognostic value of CT-based tumor volume were recently published from a multi-institutional group 43, 44 . de Perrot and colleagues published data suggesting that lower radiological tumor volume and smaller diaphragmatic tumor thickness predicted favorable outcomes in patients treated with neoadjuvant radiation followed by extra-pleural pneumonectomy (EPP) 45, 46 . In addition, a group from the UK also reported a promising random walk-based computer-aided algorithm for image segmentation 47 .
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Progresses in Pathology
The histological diagnosis of MPM is relatively well established when performed by expert pathologists, based on positive markers of mesothelial lineage and negative markers of epithelial lineage. However, diagnostic uncertainty remains common, and continued efforts to improve the accuracy of diagnosis are needed 48 . One of the most challenging differential diagnoses remains the distinction between sarcomatoid MPM and sarcomatoid carcinoma of the lung. In this respect, MUC4 may be a novel sensitive and specific immunohistochemical biomarker for sarcomatoid carcinoma of the lung 49 .
Moreover, GATA3 immunostaining may be useful to identify sarcomatoid and desmoplastic mesothelioma 50, 51 . Disabled homolog 2 (DAB2) and Intelectin-1 were reported as new positive immunohistochemical markers for epithelioid mesothelioma 52 .
Another challenging differentiation has been between MPM and reactive mesothelial hyperplasia (RMH).
While BAP1 immunohistochemistry and p16 FISH can effectively discriminate MPM from RMH, methylthioadenosine phosphorylase (MTAP) loss may also be useful when identified in combination with BAP1 loss 53 .
In addition, several studies have focused on the evaluation of biomarkers of immunological activation and infiltrating immune cells, in particular, PD-L1 [54] [55] [56] [57] . The "don't eat me" signal CD47 was also shown to be overexpressed in diffuse malignant mesothelioma, and was suggested as a potential diagnostic and therapeutic target of MPM 58 .
Molecular Advances
Previous genomic analysis identified the loss of various tumor suppressor genes as the most common molecular event in MPM. Commonly inactivated tumor suppressor genes include the cyclin-dependent kinase inhibitor 2A (CDKN2A), BRCA1 associated protein 1 (BAP1), neurofibromin 2 (NF2), and occasionally TP53. These findings have been confirmed in a recent comprehensive genomic analysis 59 . Enhanced understanding of MPM molecular aberrations has already informed the use of targeted therapies such as the FAK inhibitor (Defactinib) for tumors lacking NF2 (COMMAND study).
Unfortunately, maintenance defactinib did not improve patient outcomes and the study was terminated early. A recent publication provides a comprehensive review of molecular advances in MPM 60 .
The role of heredity in familial MPM predisposition, even without occupational asbestos exposure, has finally been proven by the discovery of germline BAP1 mutations 61 , and supported by murine modeling 62, 63 . As a result, the tumor predisposing BAP1 cancer syndrome 64 has been increasingly recognized and characterized 50, 65 . BAP1 is a deubiquitinating enzyme with several roles in regulating DNA repair and gene expression 66 . In addition to germline mutations predisposing to mesothelioma and other cancers, BAP1 is the most frequent acquired (somatic) mutation in sporadic mesothelioma 67, 68 . In 2017, both pleural and peritoneal mesotheliomas were shown to have loss of BAP1 in more than 60% of cases 69, 70 confirming previous findings 67 . Novel functions of BAP1 which likely contribute to its role in cancer in general, and in MPM in particular, have been identified. Specifically, BAP1 is a master regulator of calcium-induced apoptosis via regulation of the IP3R3 receptor ubiquitination 71 , as well as of cellular glycolytic metabolism 72 , and a radical of oxygen homeostasis 73 . A novel alternative splice isoform of BAP1 that misses part of the catalytic domain has also been described, and it appears to regulate DNA damage response and influence drug sensitivity 74 . Furthermore, frequent germline mutations in other genes associated with DNA repair have been identified in asbestos-exposed individuals who developed MPM, suggesting theses pathways to be associated with MPM predisposition 75 . Interestingly common germline BAP1 variants appear to mediate the risk of developing renal cell carcinoma and lung cancer 76 , and possibly also MPM 77 . When mesothelioma develops in carriers of germline BAP1 mutations, these malignancies have a much better prognosis, and survival of 5 or more years is commonly seen 78 .
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In 2017 the role of BAP1 immunohistochemistry in MPM diagnosis and possibly prognosis has also been the focus of several studies. Specifically, BAP1 loss has been shown to reliably differentiate MPM from chronic pleuritis, benign mesothelial hyperplasia and other benign mesothelial lesions, as well as from other malignancies such as non-small cell lung cancer and ovarian serous tumors 53, [79] [80] [81] [82] [83] .
The identification of hereditary factors in MPM pathogenesis has also led to increased interest in the characterization of young patients. In 2017 it was reported that these patients show distinctive clinical, pathologic and genetic features, such as: higher likelihood of a past history of mantle radiation, family history of breast cancer, and lower rates of CDKN2A deletion than older patients 84 . Moreover, a subset of mesotheliomas in young patients (15%), were associated with recurrent EWSR1/FUS-ATF1 fusions 85 .
Most importantly, the presence of clinically actionable ALK rearrangements was described in about 10% of peritoneal mesothelioma, most commonly younger women 86 .
Systemic Therapies
Targeting Angiogenesis:
Systemic cytotoxic chemotherapy with pemetrexed plus cisplatin remains the only FDA approved therapy for MPM and represents the current standard of care. With treatment response rates of approximately 40% it extends median overall survival to 12-16 months 87 . As VEGF signaling is important in the pathophysiology of MPM, VEGF inhibition is being explored as a potential treatment option [88] [89] [90] [91] . Another antiangiogenic, nintedanib, is a small molecule tyrosine-kinase inhibitor targeting VEGF receptors, fibroblast growth factor receptors (FGFR), and platelet derived growth factor receptors (PDGFR). The LUME-MESO study is an ongoing randomized, double blind, placebo-controlled Phase II/III examining the efficacy and safety of adding nintedanib to standard chemotherapy in non-surgical MPM patients; phase II results were reported in 2017 94 . In 87 evaluable patients (44 nintedanib, 43 placebo), nintedanib improved progression-free survival (PFS) by 3.7 months as compared with placebo (p=0.01), most notably in those with epithelioid histology (4 months PFS, p=0.006). There was a trend towards improved overall survival (OS) (median 18.3 months versus 14.2 months) in favor of the nintedanib group, however this difference was not statistically significant; the study was not powered to examine OS. The addition of nintedanib to standard chemotherapy was safe, and these results support the rationale for the ongoing Phase III study 94, 95 (Table 1) .
Blocking Immune checkpoints:
In 2017 immunotherapy was clearly the focus of the largest number of clinical trials investigating new therapies for MPM. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is expressed on T cells, reducing the amplitude of CD28-mediated T cell activation 96 . CTLA-4 inhibition enhances T-cell activation and increases antitumor efficacy in other cancers 97 . Phase II studies investigating Tremelimumab, a selective human monoclonal antibody against CTLA-4, showed favorable PFS responses and toxicity profiles 98, 99 . In 2017, the double-blind study comparing Tremelimumab to placebo in subjects with previously treated unresectable malignant mesothelioma (DETERMINE)
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The characterization of the immunological tumor microenvironment has been the subject of considerable research, and the immune status of MPM has been distinctly correlated to prognosis 101, 102 .
Approximately 60% of MPM either expressed PD-L1 or displayed an "inflamed status" designated by a specific mRNA signature, indicating potential susceptibility to immune-directed therapy 103, 104 . Human monoclonal antibodies against PD1 and PD-L1 are approved for multiple malignancies including first line therapy for non-small cell lung cancer alone for tumors with ≥ 50% PD-L1 staining 105, 106 , or in combination with chemotherapy regardless of PD-L1 staining for adenocarcinoma 107 . There are many ongoing clinical trials investigating PD1/PD-L1 checkpoint inhibitors alone and in combination.
Single agent immunotherapy trials
Between 20-40% of MPM patients express PD-L1 at various levels, and PD-L1 expression correlates with a poorer prognosis 103, 108 . In the KEYNOTE-028 trial, the efficacy and safety of pembrolizumab as subsequent line therapy was evaluated in 25 patients with PD-L1 positive MPM (>1% PD-L1 positivity) 109 .
Twenty percent of patients achieved a partial response, and 52% demonstrated stable disease, with a 12-month median duration of response. Furthermore, the median PFS (5.4 months) and the median OS The ongoing Phase III CONFIRM study randomizes patients requiring second line therapy to nivolumab or placebo (NCT03063450). The PROMISE-Meso study, comparing pembrolizumab to gemcitabine or vinorelbine in pre-treated, nonsurgical MPM patients is also currently recruiting (NCT02991482).
Immunotherapy combination trials
In 2017, preliminary findings have also been reported of several ongoing studies investigating combination immune checkpoint inhibition pairing anti-PD1/L1 therapy with anti-CTLA-4 therapy.
Preliminary results of the NIBIT-MESO (tremelimumab and durvalumab) 114 , MAPS-2 115 and INITIATE (both ipilimumab and nivolumab) 116 trials demonstrate potential efficacy for second line therapy of mesothelioma. MAPS-2 is a Phase II study including 108 evaluable patients treated with nivolumab versus nivolumab plus ipilimumab. While the results of the nivolumab arm were promising, the 54 patients in the combination arm had a higher DCR (51.6%), although three treatment-related deaths were also reported 115 . Sixty percent of patients in the NIBIT-MESO trial experienced adverse events, with three patients requiring study discontinuation due to treatment-related toxicity 114 . INITIATE appears to be the most favorable thus far based on preliminary data from a 12 week analysis, with a DCR of 72% and only 29% of patients who have experienced grade 3 or 4 toxicity 116 . Checkmate 743 is an ongoing randomized controlled Phase III study comparing the combination of ipilimumab and nivolumab with pemetrexed/cisplatin as first line therapy in 600 patients, and is approaching completion of enrolment 117 .
Further studies are addressing combinations of anti-PD1/L1 therapy with chemotherapy. The DREAM study is evaluating the effect of durvalumab (anti-PD-L1) plus standard chemotherapy followed by durvalumab alone and has completed recruitment 118 Table 3) .
Based on recent evidence suggesting a role for focal adhesion kinase in the regulation of the immunosuppressive microenvironment 119 , and synergy between FAK and PD1 inhibition 120 , a proof of concept phase 1b/2A clinical trial of pembrolizumab and FAK is ongoing and includes a mesothelioma cohort (NCT02758587).
While PD1/PD-L1 targeted checkpoint inhibition has demonstrated promising clinical responses in early phase studies, the results of the ongoing Phase III studies described are needed to better define the role of this approach. It is unclear whether the potentially small additional benefit of combination immune checkpoint inhibition will justify the increased toxicity.
Promising Targeted Therapies:
BAP1 Loss in MPM BAP1 plays an independent role in epigenetic regulation and malignant transformation. BAP1 loss results increased trimethylated histone H3 lysine 27 (H3K27me3), elevated enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) expression, and enhanced repression of polycomb repressive complex 2 (PRC2) targets. In preclinical models EZH2 inhibition has been shown to be beneficial in MPM with BAP1 loss 121 (Figure 1) . A Phase II clinical trial investigating the EZH2 inhibitor tazemetostat in MPM completed enrollment and results should be available soon (NCT02860286). BAP1 inactivation alters double strand DNA repair via homologous recombination 122, 123 . However, the potential implication for poly ADP ribose polymerase (PARP) inhibitor sensitivity in mesothelioma have not yet been evaluated, although the MiST 1 study is currently in development in the UK. Mesothelin is a cell surface glycoprotein expressed on cells lining the pleura, peritoneum, pericardium, as well as on MPM cancer cells 124, 125 . It is an attractive potential target in MPM due to its high surface expression 126, 127 and its suspected involvement in tumorgenesis 128 show a difference between the treatment groups 130 (Table 1) .
However, there are additional promising preclinical models. Recently, a preclinical study combining direct tumor injection of mesothelin immunotoxin with intra-peritoneal injection of anti-CTLA-4 therapy demonstrated an 86% complete response (CR) rate of in directly treated tumors and a 56% CR of a second untreated tumor while no CR occurred when both drugs were given separately 131 . A similar combination approach was also published using an anti-mesothelin immunotoxin (RG7787) plus nabpaclitaxel (albumin-bound paclitaxel) in mesothelioma cell lines. Three of four lines revealed durable CR, and studies in human patients began in 2017 132 .
Arginine deprivation therapy
Argininosuccinate synthetase 1 (ASS1) is the rate-limiting enzyme in arginine production, and cell lines deficient of ASS1 usually require exogenous arginine supplementation 133 (Figure 3) . Intratumoral ASS1 deficiency has been identified in 63% of archived mesothelioma lines, and is associated with increased tumorgenesis, and more aggressive disease [133] [134] [135] . In vitro studies of arginine deprivation with adenosine M A N U S C R I P T
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Mesothelioma 2017 deaminase (ADI-PEG20) improve progression free survival, with low toxicity [136] [137] [138] [139] [140] . Szlosarek and colleagues applied this concept to mesothelioma, conducting the first prospective biomarker-driven randomized controlled trial in this disease 141 . Forty-four patients received ADI-PEG20 plus best supportive care, and 24 patients received best supportive care only, with pre-determined interval imaging to assess for progression of disease. They observed a median PFS of 3.2 months in the treatment group as compared to 2.0 months in the control group (p =0.03) 141 ( Table 2 ). These findings led to a Phase I study of ADI-PEG20 combined with standard-of-care chemotherapy in ASS1-deficient mesothelioma and non-small cell lung cancer patients 142 . Nine patients (5 MPM) received escalating weekly doses of ADI-PEG20 with standard chemotherapy. No dose-limiting toxicities were encountered, and only nine reported adverse events were related to ADI-PEG20, most commonly rash. All patients experienced stable disease, and seven (78%) achieved a partial response, including one with sarcomatoid MPM. These results suggested co-administration of standard chemotherapy and arginine deprivation therapy in ASS1-negative patients was well tolerated and could improve tumor response over chemotherapy alone 142 . A phase II/III trial is currently recruiting MPM patients with 75% loss of ASS1 143 . and mTOR/PI3K inhibitor suppresses the growth of in NF2-mutant mesothelioma and shwannoma cells 146 .
NF2 Targeted Therapies
Other Potential Systemic Therapies
Promising results in the adjuvant setting using the WT-1 peptide vaccine galinpepimut-S after multimodality therapy were shown in a randomized phase II trial, but lacked statistical power to draw stronger conclusions 147 . Autologous monocyte-derived dendric cell immunotherapy pulsed with allogenic tumor cell line lysate was effective in mice, and safe in 9 MPM patients in a phase I trial 148 . A novel therapeutic strategy currently at a preclinical stage for MPM is the inhibition of the pro-tumor alarmin HMGB1 by a number of compounds such as ethyl pyruvate 149 and aspirin 150 .
The antitumoral properties of various viruses have been demonstrated in a number of malignancies [151] [152] [153] [154] [155] . MPM has been the target of many such investigations 156 , and promising preclinical data regarding adenovirus oncotherapy [157] [158] [159] [160] prompted human studies. HSV-1 oncotherapy has shown dramatic responses in vitro [161] [162] [163] , and preliminary results in human patients revealed a 50% disease stability 164 . In murine xenografted models of mesothelioma, intrapleural oncolytic vaccinia virus administration resulted in improved 30 day survival 165 . There have also been several promising studies of MPM and intraplural administration of oncolytic measles viruses 166, 167 , and a phase I study is ongoing to evaluate efficacy in humans 168 .
Other promising therapeutic candidates include the monopolar spindle 1 kinase, a kinase of the spindle assembly checkpoint that controls cell division and cell fate 169 ; the mTOR/PI3K/AKT axis for the aggressive subset of MPM harboring simultaneous inactivating mutations of the genes LATS2 and targeting of MYC which is upregulated in MPM cells 172 . The first-in-human phase I trial of anti-CD26 antibody, YS110, was also conducted for 33 patients including 22 MPM patients 173 .
Several microRNAs have been reported as potential therapeutic targets with proof of concept in clinical trials, e.g. the microRNA-15/16 family 174, 175 , or the microRNA-137, through its control of YB-1 176 .
Interestingly, microRNAs have been shown to contribute to the regulation of PD-L1 expression 177 , opening to novel potential combinations between microRNA-targeting drugs and immune checkpoint inhibitors.
To further bridge preclinical and clinical results, the availability of relevant in vitro and in vivo models is crucial. In this respect, the establishment of primary MPM culture systems to test novel drugs 178, 179 as well as of patient-derived xenografts from pleural mesothelioma 180 represented a significant scientific advance in 2017.
Surgical resection
Optimal treatment of MPM remains controversial, particularly the role of localized therapies such as surgery and radiation. Historically, operable patients underwent EPP, which has significant complications and substantial mortality, with no appreciable benefit to the patient demonstrated by the small randomized MARS pilot study 181 . Pleurectomy/decortication (P/D) was then introduced in an attempt to offer a lung-sparing macroscopic resection of the tumor. Previous uncontrolled studies have suggested that this procedure is associated with fewer adverse events, with equivalent to improved survival benefits [182] [183] [184] [185] [186] [187] [188] . Despite these findings, clinical equipoise regarding the true benefit of either operation remains. In 2017, two large observational studies using the National Cancer Database were conducted. In the first, propensity score matching analysis showed that surgery-based multimodality M A N U S C R I P T
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Mesothelioma 2017 therapy was associated with improved survival and may offer therapeutic benefit among carefully selected patients 189 . A second study evaluated 271 patients who underwent EPP, and 1036 patients who received P/D. They found no statistically significant differences in OS (19 months in the EPP group and 16 months in the P/D group; p=0.120), 30-day mortality (5%, p=0.999), or 30-day readmission rates (7% versus 5%; p=0.292), implying either technique was a realistic option for surgical candidates 190 . To further complicate the debate, a relatively large retrospective multicenter study suggested that extended P/D or non-extended P/D (i.e. P/D without resection of the diaphragm and/or pericardium) had similar outcomes in terms of early results and survival rate 191 . A recently published comprehensive review on quality of life (QoL) in MPM showed that QoL was generally better for patients undergoing P/D compared to EPP 192 . Presently, the ongoing MARS2 trial is comparing P/D versus no surgery; in 2017 the study surpassed its futility endpoint and patient enrollment will continue 193 .
Advances in Radiotherapy
The ostensible goal of surgery in MPM has been macroscopic complete resection. Surgical resection alone is associated with frequent loco-regional recurrences 187, 194 , suggesting adjuvant or neoadjuvant radiotherapy (RT) in a multimodality approach may have a role in improving recurrence control.
However the role of RT following EPP has been questioned based on a recently published randomized controlled study 195 .
A systematic review assessing the role of RT following lung sparing surgery (P/D) in MPM 196 concluded that RT can be delivered safely with encouraging survival data and acceptable levels of toxicity after a lung sparing procedure in MPM. Memorial Sloan-Kettering Cancer Center has been at the forefront of research regarding IMRT after P/D, with studies demonstrating encouraging OS without significant increase in radiation pneumonitis [197] [198] [199] improved OS in the IMRT arm (median 20.2 versus 12.3 months, p = 0.001). Notably patients in this arm was also more likely to have achieved a macroscopically complete resection (p=0.01), to have epithelial histology (p=0.003), had higher Karnofsky performance scores upon initial receipt of RT (p=0.01), and were less likely to experience esophagitis (p=0.0007) by multivariable analysis. There were no significant differences in rates of local recurrence 200 .
Another promising approach has been neoadjuvant high-dose RT to the ipsilateral lung, followed by EPP, pioneered by the Toronto group lead by Drs. de Perrot and Cho. This approach has been shown to be safe and demonstrated a very favorable OS 201, 202 . This group treated 90 patients between November 2008 and February 2017, with a median survival of 28.3 months for the intention-to-treat population.
This approach may be most beneficial in patients with epithelial tumors, low tumor volume and no lymph node metastasis 45, 195 .
Of note, carriers of germline BAP1 mutations may have a high risk of developing a second malignancy when treated with radiation therapy. Therefore, radiation therapy should be used with caution, similar to the treatment guidelines for patients with Li-Fraumeni syndrome.
Advances in Palliative Care
In contrast to lung cancer, a recently reported randomized study did not demonstrate any benefit of early implementation of palliative care for MPM (RESPECT-Meso Study) 203 . It is worth noting that the RESPECT study was conducted in the United Kingdom and Australia by centers with significant nursing support for patients, and its conclusions do not necessarily negate the potential benefit of palliative care M A N U S C R I P T
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Mesothelioma 2017 in other healthcare settings. In addition, the recently presented PIT Study demonstrated that prophylactic intervention track site radiation did not prevent the occurrence and symptoms of tract site metastasis. The frequency of tract site metastasis was not significantly different; 3.2% in the radiotherapy group and 5.3% in the control group 204 .
Furthermore, recent data demonstrated that the use of an indwelling pleural catheter resulted in fewer hospital days and fewer subsequent interventions than talc slurry pleurodesis in a randomized study of 144 patients (approximately 25% of patients in each group had MPM) 205 . It is important to note, however, that clinical concern remains for seeding along a chest tube tract in MPM patients 206 .
Conclusion
The year 2017 was characterized by several important advances in this field, although only a minority would be considered practice changing. As of today, pemetrexed based cytotoxic chemotherapy with or without bevacizumab remains the standard of care for most patients. Immunotherapy trials remain an exciting area of investigation, though it remains unclear if the benefits of combination anti-CTLA-4 and anti-PD-1/L-1 immunotherapy will outweigh the increased risk of toxicity. Many single agent and combination immunotherapy trials are ongoing, and additional results are expected for 2018/19. While physician-directed immune checkpoint inhibitor therapy has now been included into the current NCCN guidelines as an option for second line therapy of MPM, the efficiency of this approach remains unproven, and as such these patients should primarily be encouraged to enroll into ongoing clinical trials.
Improved understanding of MPM molecular biology and the immunological tumor microenvironment provide future therapeutic applications, most notably via the BAP1 pathway.
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While the role of multimodality therapy including surgery remains controversial, it is encouraging that there are several new approaches and ongoing multicenter studies. The MARS-2 study surpassed its futility endpoint and preliminary findings are expected in the upcoming years. The 2017 advances will hopefully be followed by significant clinical translation and result in the urgently needed improved therapeutic strategies for this devastating disease. These studies were included in the table as they are ongoing clinical trials on human patients, but have yet to publish results. This is a complete list as of November 2017. These studies were included in the table as they were non-immunotherapy clinical trials on human patients, with some published results in 2017. This is a complete list as of November 2017. 
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